Importance of immunoglobulin therapy for COVID-19 patients with lymphocytopenia
Background The global coronavirus disease 2019 (COVID-19) was announced as pandemic by the World Health Organization (WHO). With the increased number of infected and dead victims daily all over the world, it becomes necessary to stop or overcome its rapid spread. Main body Although the production of vaccine or even specified effective anti-virus may take about six months to a year, intravenous immunoglobulin (IVIg) may be clinically used as a safe treatment to save and improve the quality of life of patients with a variety of immunodeficiency diseases such as lymphocytopenia, which is a common clinical feature in COVID-19. Conclusion Through the current review, it was concluded that this passive immunization may promote the immunity to better fight against the virus, so the survival of the patients could be kept longer. The efficacy of immunotherapy with IVIg would be greater if the immune IgG antibodies were collected from convalescent plasma therapy..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:45 |
|---|---|
| Enthalten in: |
Bulletin of the National Research Centre - 45(2021), 1 vom: 22. Feb. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Nabih, Heba K. [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Themen: |
COVID-19 |
|---|
| doi: |
10.1186/s42269-021-00502-4 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
SPR043279708 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR043279708 | ||
| 003 | DE-627 | ||
| 005 | 20230519130713.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 210223s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1186/s42269-021-00502-4 |2 doi | |
| 035 | |a (DE-627)SPR043279708 | ||
| 035 | |a (DE-599)SPRs42269-021-00502-4-e | ||
| 035 | |a (SPR)s42269-021-00502-4-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 500 |q ASE |
| 082 | 0 | 4 | |a 500 |q ASE |
| 100 | 1 | |a Nabih, Heba K. |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Importance of immunoglobulin therapy for COVID-19 patients with lymphocytopenia |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Background The global coronavirus disease 2019 (COVID-19) was announced as pandemic by the World Health Organization (WHO). With the increased number of infected and dead victims daily all over the world, it becomes necessary to stop or overcome its rapid spread. Main body Although the production of vaccine or even specified effective anti-virus may take about six months to a year, intravenous immunoglobulin (IVIg) may be clinically used as a safe treatment to save and improve the quality of life of patients with a variety of immunodeficiency diseases such as lymphocytopenia, which is a common clinical feature in COVID-19. Conclusion Through the current review, it was concluded that this passive immunization may promote the immunity to better fight against the virus, so the survival of the patients could be kept longer. The efficacy of immunotherapy with IVIg would be greater if the immune IgG antibodies were collected from convalescent plasma therapy. | ||
| 650 | 4 | |a COVID-19 |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Lymphocytopenia |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Immunoglobulins |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Immunotherapy |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Passive immunization |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Convalescent plasma therapy |7 (dpeaa)DE-He213 | |
| 773 | 0 | 8 | |i Enthalten in |t Bulletin of the National Research Centre |d Berlin : Springer, 2018 |g 45(2021), 1 vom: 22. Feb. |w (DE-627)SPR038512009 |w (DE-600)2946659-3 |x 2522-8307 |7 nnns |
| 773 | 1 | 8 | |g volume:45 |g year:2021 |g number:1 |g day:22 |g month:02 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1186/s42269-021-00502-4 |z kostenfrei |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_SPRINGER | ||
| 912 | |a SSG-OLC-PHA | ||
| 951 | |a AR | ||
| 952 | |d 45 |j 2021 |e 1 |b 22 |c 02 | ||